Download DNAVac Title: Development and production of DNA vaccines

DNAVac
Title: Development and production of DNA vaccines without antibiotic resistance gene
Keywords : DNA vaccine, Antibiotic resistance, DNA production
Consortium
Companies: Delphi Genetics SA (coordinator), Eurogentec
Research centers: Ulg (Laboratory of Immunology-vaccinology), UCL (Unit of galenic
pharmacy)
Topic of the project
Today vaccination is an uncontested way of fighting disease. DNA vaccination seems to be a
particularly promising method at this time. For this application, plasmid DNA is injected into
the subject (man or animal). This plasmid DNA encodes for an antigen that will be produced
by the subject’s cells. In addition to the antigen, the plasmid also encodes for a resistance to
an antibiotic used during the construction and production of the molecule. This resistance is
increasingly less tolerated by the regulatory agencies (FDA and EMA). In the context of this
project, we are proposing to replace this resistance to an antibiotic by a selection system
based on bacterial genes that have already been used by Delphi Genetics for the production
of proteins without an antibiotic-resistance gene.
The project’s objective is threefold:
1) To develop a technology enabling DNA vaccines to be formulated quickly and without
antibiotic-resistance genes.
2) To obtain sufficient scientific data to constitute a file for FDA or USDA and EMA
3) To proceed with at least three examples of effective DNA vaccines in the veterinary
field
Budget
This is a 3 years project with a total budget of 2,6 M€
Status of the project: ongoing
Contact
Cédric Szpirer (coordinator of the project)
E-mail: [email protected]
Delphi Genetics SA
Web site : www.delphigenetics.com
BioWin a.s.b.l. – Point Centre – 19 rue Georges Lemaître – B-6041 Charleroi – Belgium
Tel. + 32 71 376 386 – Fax + 32 71 376 387 - T.V.A. BE (0)882768591 - ING: 363-0030127-97
e-mail : [email protected] - http://www.biowin.org